Skip to content

908 Devices MASS Stock-Based Comp

Stock-Based Comp at other companies

Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO
$83M+10.7%
WAT
Waters CorporationWAT
$20M+53.8%
Agilent Technologies logo
Agilent TechnologiesA
$32M+6.7%
Mettler-Toledo International, Inc. logo
Mettler-Toledo International, Inc.MTD
$5.47M+6.4%
Danaher logo
DanaherDHR
$58M-4.9%
Idexx Laboratories logo
Idexx LaboratoriesIDXX
$16.34M+11.8%

Other financials

Income statement

See full
Revenue$13.4M+13.6%
Gross profit$6.9M+24.2%
Operating income-$12.9M-16.9%
Net income-$12.0M-127%
EPS (diluted)-$0.32-126%

Balance sheet

See full
Cash & equivalents$67.6M-14.7%
Total debt$4.5M+18.6%
Total equity$134.2M-15.8%
Total assets$186.7M-4.8%

Cash flow

See full
Operating cash flow$1.2M+108%
CapEx$40.0K-74.8%
Free cash flow$1.2M+108%

Valuation

See full
Market cap$339.57M+29.0%
Enterprise value$276.47M+47.2%
P/S5.9×+0.8×

Profitability

See full
Gross margin51.5%+1.3pp
Operating margin-76.8%-19.6pp
Net margin-62.4%+323pp
FCF margin-16.7%-7.2pp

Returns & leverage

See full
Return on equity-24.6%-149pp
Debt / equity0.0×
Current ratio3.6×-4.0×

Where this comes from

Reported directly by 908 Devices in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The official record: 908 Devices’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about 908 Devices's stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is 908 Devices's stock-based comp?
908 Devices (MASS) reported stock-based comp of $2.4M in Q1 2026.
How has 908 Devices's stock-based comp changed year-over-year?
908 Devices's stock-based comp increased by 1.4% year-over-year, from $2.37M to $2.4M.
What is the long-term trend for 908 Devices's stock-based comp?
Over 4 years (2021 to 2025), 908 Devices's stock-based comp has grown at a 40.8% compound annual growth rate (CAGR), from $2.5M to $9.85M.
What does stock-based comp mean?
Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.